Draft on electronic submissions raises concerns for BIO

02/28/2013 | OutSourcing-Pharma.com

Draft guidelines from the FDA on the electronic submission of data from clinical sites don't ensure that industry can rely on technical specifications to allow long-term planning, BIO said. The guidelines should address duplicative submissions that can delay site inspections, Pharmaceutical Research and Manufacturers of America said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY